


AMENDMENTS TO THE CLAIMS

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (previously presented): A triaza-cyclopenta[cd]indene derivative represented by the following formula [I]:



(wherein R¹ and R² are the same or different, and independently are hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl, C₁₋₆alkoxy-C₁₋₆alkyl, hydroxy-C₁₋₆alkyl, cyano-C₁₋₆alkyl, carbamoyl-C₁₋₆alkyl or di(C₁₋₆alkyl)amino-C₁₋₆alkyl, cyano, carbamoyl or aryl;

R³ is hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl, halogen, C₁₋₆alkoxy, C₃₋₇cycloalkyloxy, C₁₋₆alkylthio or -N(R⁶)R⁷;

R⁴ is hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl or C₃₋₇cycloalkyl-C₁₋₆alkyl;

R⁵ is hydrogen, C₁₋₆alkyl, aryl-C₁₋₆alkyl or carbamoyl;

Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkylsulfinyl, C₁₋₆alkylsulfonyl, cyano, nitro, hydroxy, -CO₂R⁸, -C(=O)R⁹, -CONR¹⁰R¹¹, -OC(=O)R¹², -NR¹³CO₂R¹⁴, -S(=O)_rNR¹⁵R¹⁶, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy and -N(R¹⁷)R¹⁸;

R⁸ and R¹⁴ are the same or different, and independently are hydrogen or C₁₋₅alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₅alkyl, aryl or aryl-C₁₋₅alkyl;

R⁶, R⁷, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁵, R¹⁶, R¹⁷ and R¹⁸ are the same or different, and independently are hydrogen, C₁₋₆alkyl or C₃₋₇cycloalkyl;

r is 1 or 2;

or individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

2. (original): The triaza-cyclopenta[cd]indene derivative according to claim 1 represented by the formula [I], wherein R³ is C₁₋₆alkyl; R⁴ is hydrogen or C₁₋₆alkyl; R⁵ is hydrogen or C₁₋₆alkyl; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkylthio, trifluoromethyl, trifluoromethoxy and -N(R¹⁷)R¹⁸ (wherein R¹⁷ and R¹⁸ are the same or different, and independently are hydrogen or C₁₋₃alkyl); R¹, R² and R⁴ are as defined in claim 1, or pharmaceutically acceptable salts and hydrates thereof.

3. (original): The triaza-cyclopenta[cd]indene derivative according to claim 1 represented by the formula [I], wherein R^3 is C_{1-3} alkyl; R^5 is hydrogen or C_{1-3} alkyl; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C_{1-3} alkyl; R^1 , R^2 and R^4 are as defined in claim 1, or pharmaceutically acceptable salts and hydrates thereof.

4. (currently amended): A composition comprising a triaza-cyclopenta[cd]indene derivative, a pharmaceutically acceptable salt thereof or its hydrate according to claim 1, as an active ingredient and a pharmaceutically acceptable carrier.

5. (previously presented): A method for treating depression or anxiety comprising administering to a patient in need of treatment a pharmaceutically effective amount of the triaza-cyclopenta[cd]indene derivative, a pharmaceutically acceptable salt thereof or its hydrate according to claim 1.